강추룰렛<- 바로가기 BEAVERTON, ORE.--( / ) October 01, 2021 -- USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced new Certified USB Type-C® Cable power rating logos to clearly indicate the power capabilities of USB-C® cables to consumers. Certified USB Type-C Cables will now feature logos highlighting support for 60W or 240W of power as defined by the recently published USB Power Delivery (USB PD) 3.1 Specification.
Additionally, the Certified USB4™ Logos have been updated to unify branding across the Certified USB Logo Program, offering consumers a simple way to identify the performance and power capabilities of certified USB cables, hosts, devices, and chargers.
“With the new higher power capabilities enabled by the USB PD 3.1 Specification, which unlocks up to 240W over a USB Type-C cable and connector, USB-IF saw an opportunity to further strengthen and simplify its Certified Logo Program for the end user,” said Jeff Ravencraft, USB-IF President and COO. “With our updated logos, consumers can easily identify the USB4 performance and USB Power Delivery capabilities of Certified USB-C Cables, which support an ever-expanding ecosystem of consumer electronics from laptops and smartphones to displays and chargers.”
Certified USB solutions ensure interoperability and backwards compatibility in the marketplace and USB-IF reminds consumers to purchase certified products from trusted sources that display USB-IF Certified Logos on packaging, product briefs, or the device, charger, and cable itself. To learn more about the Certified USB Compliance and Logo Program, please visit
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at
USB4™, USB Type-C® and USB-C® are trademarks of USB Implementers Forum.
View source version on businesswire.com:USB-IF Announces New Certified USB Type-C® Cable Power Rating Logos
INGELHEIM, GERMANY 신문로1가화투치기 & INDIANAPOLIS--( / ) December 19, 2016 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today adopted a positive opinion to update the Jardiance® (empagliflozin) label including a change to the indication statement. The CHMP recommends Jardiance® for the treatment of adults with 신문로1가화투치기 다운로즈 insufficiently controlled type 2 diabetes mellitus (T2D) as an adjunct to diet and exercise. The recommended product information now includes data on the 밤열한시닷컴 INGELHEIM,of risk of cardiovascular (CV) death in patients with T2D and established CV disease in addition to data on the improvement of blood sugar control in patients with T2D. Jardiance® is the only oral diabetes treatment shown to reduce the risk of CV death in a dedicated CV outcome trial to 신문로1가화투치기 sexmovies date.
The positive opinion is based on results from the EMPA-REG OUTCOME® trial. The trial demonstrated that Jardiance® 신문로1가화투치기 sexstory significantly reduced the risk of the primary endpoint 보솜이 TheCV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo when added to standard of care in adults with T2D and established CV disease. Taking Jardiance® on top of standard of care reduced the risk of dying from CV disease by 38 percent. There were no statistically significant differences in the risk 신문로1가화투치기 메가카지노 of non-fatal heart attack or non-fatal stroke.
“Cardiovascular disease is the number one 신문로1가화투치기 cause of death among people with type 2 diabetes. The life expectancy of people with type 신문로1가화투치기 2 diabetes and cardiovascular disease is up to 12 years shorter. There is 신문로1가화투치기 일본애니메이션 a significant need for therapies which add to and go beyond the current standard of care,” said Professor Hans-Juergen Woerle, Global Vice President Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “Therefore, this recommendation by the CHMP is an important step towards addressing and reducing the burden of cardiovascular mortality for people with type 2 diabetes.”
On December 2, the U.S. Food and 신문로1가화투치기 넷마블 강추룰렛 넷마블 Drug Administration (FDA) approved a new indication for 스포츠토토예상 Onto reduce the risk of CV death in adults with 신문로1가화투치기 스타바카라주소 T2D and established CV disease.
About the 신문로1가화투치기 레이스툰 EMPA-REG OUTCOME® 한국기사 About신문로1가화투치기
EMPA-REG OUTCOME® was a long-term, multicentre, 신문로1가화투치기 호두티비 randomised, double-blind, placebo-controlled trial of more than 7,000 섹스비디오 EMPA-REGfrom 42 countries 신문로1가화투치기 오피어때 with T2D and established 신문로1가화투치기 CV disease.
The study assessed 신문로1가화투치기 도메인이 the effect of Jardiance® (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of sugar-lowering 섹스비디오 Theand 신문로1가화투치기 토마토렌트 CV drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of CV death, non-fatal heart attack or non-fatal stroke.
Over a median 신문로1가화투치기 of 3.1 years, Jardiance® significantly reduced the risk of CV sex.com Overnon-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced 신문로1가화투치기 W툰 by 38 percent, with 신문로1가화투치기 강원랜드바카라주소 no significant difference in the risk of non-fatal heart attack or non-fatal stroke.
The overall safety profile of Jardiance® in the EMPA-REG OUTCOME® 강추룰렛 블랙잭카지노주소 trial was consistent with that of previous 신문로1가화투치기 trials.
About 신문로1가화투치기 게임사이트바카라주소 Diabetes and Cardiovascular 신문로1가화투치기 쓰레빠닷컴 Disease
More than 415 million 강추룰렛 게임사이트카지노추천 people worldwide have diabetes, of which 193 million are estimated to be undiagnosed. By 2040, the number of people with diabetes is expected to rise to 642 million people worldwide. T2D is the most common form of diabetes, responsible for up to 신문로1가화투치기 91 percent of diabetes cases in high-income countries. Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.
Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, CV disease is a major complication 신문로1가화투치기 and the leading cause of death associated with diabetes. People with diabetes are 강추룰렛 토렌트쇼미 two to four times more likely to develop CV disease than people without diabetes. In 2015, diabetes caused 5 million deaths worldwide, with CV disease as the leading cause. Approximately 50 percent of deaths in people with T2D worldwide are caused by 신문로1가화투치기 토렌트주 CV disease.
About 신문로1가화투치기 일본야동 Jardiance® 신문로1가화투치기 서양야동 강추룰렛 서양야동
Jardiance® (empagliflozin) is 신문로1가화투치기 야동 an oral, once daily, highly selective sodium-glucose co-transporter-2 (SGLT2) inhibitor approved 강추룰렛 AV for 신문로1가화투치기 MANY use in Europe, the United States and other markets around the world for the treatment of adults with T2D.
Inhibition of SGLT2 with Jardiance® 신문로1가화투치기 밤헌터 (empagliflozin) in patients with T2D and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation 신문로1가화투치기 꼬꼬TV of Jardiance® increases excretion of 신문로1가화투치기 먹튀보안관 salt from the body (i.e. sodium) and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Excretion of sugar, salt and water after the initiation of treatment with empagliflozin may therefore contribute to the improvement in 강추룰렛 초희넷 CV outcomes.
The change to the existing indication adopted by 신문로1가화투치기 이브넷 the CHMP is as follows:
Jardiance® is indicated for the treatment of adults 신문로1가화투치기 에스박스 with insufficiently controlled type 2 신문로1가화투치기 diabetes mellitus as an adjunct to diet and exercise
· 강추룰렛 먹튀캅스 as monotherapy when metformin is considered inappropriate due 신문로1가화투치기 to intolerance
· in 강추룰렛 porn addition to other 신문로1가화투치기 medicinal products for the treatment of diabetes
For study results 신문로1가화투치기 야피스 with respect to combinations, effects on glycaemic control and CV events, and the populations studied, see sections 4.4, 강추룰렛 밤꽃 4.5 and 5.1.
Jardiance® is not approved for 신문로1가화투치기 patients with type 1 신문로1가화투치기 딸기넷 diabetes or for 개툰 Jardiance®treatment of diabetic ketoacidosis 신문로1가화투치기 윈윈 (increased ketones in the blood or urine).
Intended 신문로1가화투치기 야인 Audiences 신문로1가화투치기 강추룰렛
This press release is issued from 신문로1가화투치기 해소넷 Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is 강추룰렛 소라스포 intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business. 신문로1가화투치기 뮤즈해
Please click on the 퍼니툰 Pleasebelow for 신문로1가화투치기 ‘Notes to Editors’ and ‘References’:
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through 신문로1가화투치기 야동TV the industry’s largest press release distribution network
